Evidence map›Paper›PMID 14689303›Full record

ArticleJournal of cancer research and clinical oncology2004

PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus.

F Kimura, J Watanabe, H Hata, T Fujisawa, Y Kamata, Y Nishimura, T Jobo, H Kuramoto

Open access · greenAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 47 citations in OpenAlex.

  1. Precise Immunodetection of PTEN Protein in Human Neoplasia.Cold Spring Harbor perspectives in medicine · 2019
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

F KimuraDepartment of Clinical Cytology, Graduate School of Medical Sciences, Kitasato University, Kitasato, Kanagawa, Japan.
J Watanabe
H Hata
T Fujisawa
Y Kamata
Y Nishimura
T Jobo
H Kuramoto
Kitasato University Medical Center · JPKitasato University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePTEN is a tumor suppressor gene that inhibits cell proliferation by regulating intracellular signaling pathways, and this activity can be abolished by mutations of the PTEN gene. This study was designed to examine the correlation of PTEN expression with the expression of cell cycle regulators and with clinicopathological parameters in endometrioid adenocarcinoma of the uterine corpus.

methodsTissue samples of 117 endometrioid adenocarcinomas in addition to those of 19 normal endometria and 20 endometrial hyperplasias were used for the study. Immunohistochemical staining for PTEN protein was performed with the labeled streptavidin-biotin method on formalin-fixed and paraffin-embedded tissue samples. PTEN expression was represented as the staining score.

resultsImmunohistochemistry showed that the nuclei of cells were positive for PTEN. The PTEN staining score of normal endometrium was significantly higher in the proliferative phase than in the secretory phase. The scores of various endometrial hyperplasias were not significantly different from each other, regardless of the type of hyperplasia. The PTEN staining scores of endometrioid adenocarcinomas were 7.6+/-5.2 in G1, 9.6+/-5.2 in G2, and 11.9+/-3.7 in G3, and increased significantly as the histological grade increased. PTEN staining score was not significantly correlated with clinicopathological parameters such as FIGO stage, myometrial invasion, lymph-vascular space invasion (LVSI), lymph node metastasis or group, but was significantly correlated with labeling indices (LIs) of cell cycle regulators such as Ki-67, cdk2, cyclin A, cyclin D1, cyclin E, p27, and p53. The PTEN staining score of p53-wild cases was significantly lower than that of p53-mutant ones, but there was no significant difference of the score in cases with different PTEN gene status. PTEN expression was significantly lower in cases with both high levels of estrogen receptor and progesterone receptor.

conclusionPTEN protein expression was decreased in well-differentiated and less growth-aggressive endometrial carcinoma with wild-type p53 gene and high levels of ER and PR. This suggests that disturbed PTEN expression occurs in an early phase of the tumorigenesis of well-differentiated endometrial carcinoma.

Indexed as

Gene Expression Regulation, NeoplasticNeoplasm InvasivenessAdenocarcinomaBiomarkers, TumorCarcinoma, EndometrioidCDC2-CDC28 KinasesCell Cycle ProteinsCell DifferentiationCyclin ACyclin D1Cyclin-Dependent Kinase 2Cyclin-Dependent Kinase Inhibitor p27Cyclin EEndometrial HyperplasiaFemaleHumansBiomarkers, TumorCDC2-CDC28 KinasesCDK2 protein, humanCell Cycle ProteinsCyclin ACyclin D1Cyclin-Dependent Kinase 2Cyclin-Dependent Kinase Inhibitor p27Cyclin EKi-67 AntigenPhosphoric Monoester HydrolasesPTEN PhosphohydrolasePTEN protein, humanReceptors, EstrogenReceptors, ProgesteroneTumor Suppressor Protein p53Tumor Suppressor Proteins

Identifiers

PMID14689303
PMCPMC12161819
OpenAlexW2056831135

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.